Brazil’s pharmaceutical market plays an important role in Latin America and is one of the largest markets in the ’emerging world’ with over 100 million inhabitants which has challenged the capabilities of the universal, public and free health system. The guidelines on the inclusion and exclusion of health technologies into the national health system (SUS) render the entire process more transparent for all stakeholders involved. Manufacturers will certainly benefit from such an initiative, as the selection and prioritisation process will become more predictable. This will allow manufacturers to be better prepared for the HTA process, for their established and new medicines.
MAP Tag Cloud
Use the word cloud below to search for common topics – the larger the font, the more frequently it occurs.